As shown in Fig. 5A,B, ERK1/2 knockdown mimics the actions of metformin on gemcitabine-resistant pancreatic cancer cells that inhibiting cell proliferation and decreasing CD133+ cell proportion. Here, MAPK3 is linked to pancreatic neoplasm.